MarketVIEW: CAR-T r/r B-ALL global market forecast
Published: May 2017
Acute Lymphoblastic Leukaemia (ALL) is a hematologic malignancy characterised by the proliferation and accumulation of lymphoid progenitor cells (lymphoblasts) or lymphocytes in the bone marrow, blood or in various extramedullary sites.
ALL, which mainly affects the <20 yrs age group represents about 0.4% of all new cancer cases in the US with around 6500 new cases per year and ~1400 deaths (SEER, Cancer Stat Facts).
Rates for ALL have been rising ~0.6% each year for the last 10 years although the 5-year survival rate shows an increasing trend.
Despite a plethora of treatment strategies and a relatively high cure rate in children (60-90%), the prognosis of those individuals with relapsing/refractory disease (r/r) is still poor. In adults, long term survival (5 year rates) are often below 10%.
No current standard approach exists. CAR-T or Chimeric Antigen Receptor T cells are a promising new treatment intervention for r/r B-ALL with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies.
Recently, Novartis has received a FDA priority review for CTL019 (tisagenlecleucel-T) upon BLA filing for pediatric and young adult patients for r/r B-cell ALL.
This MarketVIEW product consists of a detailed Executive presentation (~130 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in both pediatric and adult r/r B-ALL(new cases) across 9 major Western markets to 2030.
A patient-based flow methodology has been devised where three possible intervention scenarios for CAR-T introduction are visualized so that the optimum product positioning can be assessed.
In addition, an up-to-date review of B-ALL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T landscape.
Pricing and cost effectiveness considerations are also discussed. All assumptions are clearly provided.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MS Excel WORKBOOK